Abstracts Archive - Page 1666 of 2425 - ACR Meeting Abstracts

Abstract Number: 2910 • 2015 ACR/ARHP Annual Meeting
How Accurate Is Spot Urine Protein/Creatinine Ratio in Measuring the Change over Time in Proteinuria Level Compared to the 24 Hour Proteinuria Test?
Jorge Medina-Rosas¹, Murray Urowitz^2,3, Jiandong Su², Dafna Gladman² and Zahi Touma², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Protein/Creatinine ratio in a spot urine sample (PCR) has been accepted as a substitute for the protein content in a 24 hours urine…
Abstract Number: 2911 • 2015 ACR/ARHP Annual Meeting
Tubulointerstitial Involvement in Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Tubulointerstitial disease is frequent in lupus nephritis (LN) with immune deposits being present in up to one third of patients.[1,2] Lesions including interstitial infiltration,…
Abstract Number: 2912 • 2015 ACR/ARHP Annual Meeting
Concomitant Kidney Disease in Patients with Lupus Nephritis
Paul Hoover¹, Jose A. Gomez Puerta², Alexander Fine¹, Helmut Rennke³ and Karen H. Costenbader⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Grupo de Inmunología e Inmunogenética, GICIG, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia, ³Pathology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology & Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The most common and clinically and histologically best-characterized SLE kidney disease is lupus nephritis (LN). However, other forms of kidney disease can and do…
Abstract Number: 2913 • 2015 ACR/ARHP Annual Meeting
Intensified Treatment of B Lymphocyte Depletion (ITBLD) without Immunosuppressive Maintenance Treatment As a Rescue Therapy in Refractory Lupus Nephritis (LN): A 4-Year Observation
Dario Roccatello¹, Savino Sciascia², Daniela Rossi¹, Carla Naretto³, Simone Baldovino³, Mirella Alpa³, Ilaria Salussola³ and Vittorio Modena³, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ³CMID, Torino, Italy
Background/Purpose: B-lymphocytes (BL) play a critical role in Systemic Lupus Erythematosus (SLE). BL depletion therapy still remains an attractive option, despite the disappointing results of…
Abstract Number: 2914 • 2015 ACR/ARHP Annual Meeting
Modifiable and Non-Modifiable Correlates of Satisfaction with Care in Systemic Lupus Erythematosus
Syed Alam¹, Nisarg Gandhi², Alana Nevares¹, Ailda Nika², Winston Sequeira² and Meenakshi Jolly³, ¹Internal Medicine, Cook County Hospital, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Systemic Lupus Erythematosus (SLE) a chronic disease, predominantly of young women, which may involve various organs, and is marked by periods of disease flares,…
Abstract Number: 2915 • 2015 ACR/ARHP Annual Meeting
The Utility of Lupus Serology in Predicting Outcomes of Renal Transplantation in Lupus Patients: Systematic Review and Analysis of a Large Lupus Cohort
Kristy Yap¹, Murray Urowitz^1,2, Quenby Mahood³, Jorge Medina-Rosas⁴, Arthy Sabapathy⁵, Daeria Lawson⁴, Jiandong Su¹, Dafna Gladman¹ and Zahi Touma¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Library Services, Institute of Work and Health, Toronto, ON, Canada, ⁴Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To study the utility of lupus serology as a predictor for kidney graft outcome in: a) a systematic review (SR) of the literature and…
Abstract Number: 2916 • 2015 ACR/ARHP Annual Meeting
Analysis of Risk Factors of the Progression to Chronic Kidney Disease and Comorbidities in Lupus Nephritis
Yoichiro Akiyama, Takeo Sato, Takamasa Murosaki, Katsuya Nagatani, Masahiro Iwamoto and Seiji Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: Many studies have reported long-term outcomes including morbidity, mortality, and end stage kidney disease (ESKD) in patients with lupus nephritis (LN). We aimed to…
Abstract Number: 2917 • 2015 ACR/ARHP Annual Meeting
Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?
Ryota Sakai¹, Akiko Shibata¹, Kentaro Chino¹, Jun Kikuchi², Tsuneo Kondo¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano¹, ¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Using light microscopy (LM) or immunofluorescence (IF), combined proliferative and membranous lupus nephritis (LN) is defined as an active proliferative class III/IV lesion and…
Abstract Number: 2918 • 2015 ACR/ARHP Annual Meeting
Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery?
Zahi Touma¹, Murray Urowitz^2,3, Jorge Medina-Rosas⁴, Jiandong Su¹ and Dafna Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The tempo of Complete Proteinuria Recovery (CPR) in Lupus Nephritis (LN) is slow and while 28% achieve CPR at year 1 this increases to…
Abstract Number: 2919 • 2015 ACR/ARHP Annual Meeting
Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis
Krishan Gupta¹, Manish Rathi², Navin Pattanashetti³, Ritambhra Nada⁴ and Aman Sharma⁵, ¹Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Junior Resident, Chandigarh, India, ⁴Histopathology, Professor, Chandigarh, India, ⁵Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: In addition to glomerular lesion, renal vascular lesion is also an important prognostic marker of lupus nephritis (LN). Among various vascular changes thrombotic microangiopathy…
Abstract Number: 2920 • 2015 ACR/ARHP Annual Meeting
Time to Recovery of Individual Lupus Manifestations on Standard of Care Treatment
Zahi Touma¹, Dafna Gladman¹, Jiandong Su¹ and Murray Urowitz^2,3, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Musculoskeletal, dermal and renal systems are the most commonly represented systems in lupus clinical trials. Thus, it is very important to study the time…
Abstract Number: 2921 • 2015 ACR/ARHP Annual Meeting
Lupus Nephritis: An Exploration of Management Style
Abhishek Nandan¹, Huzaefah Syed², Christen Vagts¹ and Jason Kidd¹, ¹Virginia Commonwealth University Medical Center, Richmond, VA, ²Rheumatology, Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: We aim to evaluate the differences and rationale behind the diagnostic and therapeutic approaches to proliferative lupus nephritis (LN) among nephrologists and rheumatologists. Methods:…
Abstract Number: 2922 • 2015 ACR/ARHP Annual Meeting
HLA-Specific Antibody Profile in Renal Transplant Patients with Systemic LUPUS Erythematosus
Diana Girnita¹, Paul Brailey² and Alin Girnita³, ¹Division of Immunology, Allergy & Rheumatology, University of Cincinnati Medical Center, Cincinnati, OH, ²Transplant Immunology Division, University of Cincinnati Medical Center -Hoxworth Blood Center, cincinnati, OH, Oman, ³Transplant Immunology Division, University of Cincinnati Academic Health Center, Hoxworth Blood Center, Cincinnati, OH
Background/Purpose: End stage renal disease due to Systemic lupus erytematosus (SLE) is one of the autoimmune disorder leading to renal transplantation. In this single-center study…
Abstract Number: 2923 • 2015 ACR/ARHP Annual Meeting
The Effects of Disease Activity and Mood Disorders on Cognitive Function in Systemic Lupus Erythematosus
Michelle Barraclough^1,2, Rebecca Elliott^2,3, Shane McKie^2,3, Ben Parker^1,2 and Ian N. Bruce^1,2, ¹Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ³Stopford Building, Neuroscience and Psychiatry Unit, Institute of Brain and Behaviour and Mental Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) significantly affects SLE patients with many contributing causal factors. The effect of disease activity on cognitive function remains unclear and currently…
Abstract Number: 2924 • 2015 ACR/ARHP Annual Meeting
Determinants of Damage in an SLE Cohort: Real World Data
Maria Francisca Moraes-Fontes¹, Eliana Silva², Nuno Riso³ and Margarida Jacinto⁴, ¹Autoimmune Diseases Unit, Serviço Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ²Patologia Clínica, Instituto Português de Oncologia, Francisco Gentil, Lisboa, Portugal, ³Serviço de Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ⁴Medicina Interna - Serviço 1, Hospital Espírito Santo - Évora, Évora, Portugal
Background/Purpose: Across the spectra of autoimmune diseases RA stands out, as biomarkers present from the onset are associated with severity and can be a guide…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].